Genmab A/S ADS (GMAB)
Stock · NASDAQ · Health Care
$37as of 10/16/2026
Price chart
Active signals
GMAB Signal Track Record
How signals performed across all stocks →What GMAB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | +0.7% | 53% | September 30, 2026 |
| Bollinger Band Breakdown | 20 | +2.4% | 60% | May 19, 2026 |
| Bollinger Band Breakout | 19 | -0.7% | 47% | October 5, 2026 |
| 200-Day Moving Average TouchActive now | 18 | +0.2% | 56% | July 23, 2026 |
| Any 20-session window (baseline) | -0.0% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GMAB
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disea…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 3,119
- Website
- www.genmab.com/
Fundamentals
- 1-day range
- $33.73$35.02
- Market cap
- $3.83B
- P/E (trailing)
- 26.41
- P/E (forward)
- 21.86
- EPS (trailing)
- $12.69
- Dividend yield
- —
- Beta
- 0.79
- Avg. volume
- 2.53M
Forecasts
10 analyst ratings
Genmab A/S ADS Competitors
Chosen by industry and closest market cap.
- GMABGenmab A/S ADS$37▼ 2.17%Market cap $3.83BP/E 26.41$1,512$2,369
- VKTXViking Therapeutics Inc. Common Stock$25.17▼ 8.04%Market cap $3.88BP/E —$25.77$43.15
- GPCRStructure Therapeutics Inc. American Depositary Shares$21.08▼ 5.00%Market cap $3.74BP/E —$25.59$94.9
- ELVNEnliven Therapeutics Inc. Common Stock$37.32▼ 5.11%Market cap $3.67BP/E —$14.79$62.32
- TLXTelix Pharmaceuticals Limited American Depositary Shares$10.69▲ 1.14%Market cap $3.60BP/E —$6.28$13.11
- LEGNLegend Biotech Corporation American Depositary Shares$18.48▼ 6.67%Market cap $3.58BP/E —$16.24$37.5
- RCUSArcus Biosciences Inc. Common Stock$22.12▼ 3.07%Market cap $3.56BP/E —$15.38$31.74
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GMAB Genmab A/S ADS | $3.83B | 26.41 | $37 | ▼ 2.17% | $1,512$2,369 |
| VKTX Viking Therapeutics Inc. Common Stock | $3.88B | — | $25.17 | ▼ 8.04% | $25.77$43.15 |
| GPCR Structure Therapeutics Inc. American Depositary Shares | $3.74B | — | $21.08 | ▼ 5.00% | $25.59$94.9 |
| ELVN Enliven Therapeutics Inc. Common Stock | $3.67B | — | $37.32 | ▼ 5.11% | $14.79$62.32 |
| TLX Telix Pharmaceuticals Limited American Depositary Shares | $3.60B | — | $10.69 | ▲ 1.14% | $6.28$13.11 |
| LEGN Legend Biotech Corporation American Depositary Shares | $3.58B | — | $18.48 | ▼ 6.67% | $16.24$37.5 |
| RCUS Arcus Biosciences Inc. Common Stock | $3.56B | — | $22.12 | ▼ 3.07% | $15.38$31.74 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4Yahoo · 9/27/2026
- Grant of Restricted Stock Units and Warrants to Employees in GenmabYahoo · 9/24/2026
- Genmab (CPSE:GMAB) Stock Sees Modest Fair Value Cut As Analysts Weigh Pipeline RisksYahoo · 9/24/2026
- Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeekingAlpha · 9/22/2026
- 10 Health Care Stocks Whale Activity In Today’s SessionBenzinga · 9/16/2026
- Genmab A/S (GMAB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/15/2026
- HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $40 Price TargetBenzinga · 9/14/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 82.03M
- Total value held
- $2.23B
- Institutional holders
- 271
- Unknown12.93M
- Unknown9.56M
- Unknown7.97M
- Unknown4.98M
- Unknown4.54M
- Unknown4.41M
- Unknown3.66M
- Unknown3.23M
- Unknown2.46M
- Unknown2.46M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Genmab Reports Q3 DARZALEX Net Sales of $4.239 Billion
Genmab has disclosed its third-quarter 2026 net sales for its lead product, DARZALEX, at $4.239 billion. This financial update provides a direct look at the company's revenue performance for the period. The news arrives against a backdrop of rising global spending on cancer treatments, which continues to shape the oncology sector.
Genmab Reports Q3 DARZALEX Net Sales of $4.239 Billion. Genmab has disclosed its third-quarter 2026 net sales for its lead product, DARZALEX, at $4.239 billion. This financial update provides a direct look at the company's revenue performance for the period. The news arrives against a backdrop of rising global spending on cancer treatments, which continues to shape the oncology sector.